Mesoblast Limited has released a press release.
Update on tasly transaction
Filed with ASX ·
Watch Mesoblast's latest callMesoblast (ASX:MSB) Q4 2026 Earnings Call · Replay · Aug 26Read the transcript of Mesoblast (ASX:MSB) Q4 2026 Earnings Call6ix hasn’t read this filing yet.
In the deck
Earlier from Mesoblast
- MSB Enters Into Cardiovascular Alliance For China With Tasly
- MSB Enters Into US$50M Financing With NovaQuest Capital
- Key Day 100 Survival Results In P3 GvHD Trial
- Partnership For Allogeneic Cell-based Cancer Immunotherapies
- MSB Enters Into $75 Million Non-Dilutive Credit Facility
Later from Mesoblast
- Mesoblast Reports on Annual and Fourth Quarter Results
- Tasly Receives Approvals For Transaction With MSB
- Day 180 Survival Outcomes In aGvHD Phase 3 Trial
- Completion of Tasly Transaction, and Appendix 3B
- MSB Expands Partnership With JCR For Skin Disease
Follow Mesoblast into a list and get an email when it puts out news.
Follow Mesoblast